Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.
21 CFR 314.126 Adequate and well-controlled studies.
21 CFR 314.126 Adequate and well-controlled studies., “Adequate and well-controlled studies”, is a CFR section of 21 CFR Part 314, Subpart D—FDA Action on Applications and Abbreviated Applications; in force.
https://ontology.bommaritollc.com/id/01a0f094-c4d6-77d2-b09d-3e19a3d654e7
Elsewhere
Facts
| adms:identifier | |
| prov:wasDerivedFrom | |
| schema:isPartOf | |
| schema:legislationIdentifier | 21 CFR 314.126 |
| schema:legislationJurisdiction | |
| schema:legislationLegalForce | |
| schema:legislationType | |
| schema:name | Adequate and well-controlled studiesen |
| schema:url | |
| skos:prefLabel | 21 CFR 314.126 Adequate and well-controlled studies.en |
Related
Cited by (10)eli:cites
- 21 CFR 201.57 Specific requirements on content and format of labeling for human prescription drug and biological products described in § 201.56(b)(1).
- 21 CFR 201.80 Specific requirements on content and format of labeling for human prescription drug and biological products; older drugs not described in § 201.56(b)(1).
- 21 CFR 230.150 Withdrawal or revocation of approval of an application.
- 21 CFR 312.120 Foreign clinical studies not conducted under an IND.
- 21 CFR 314.125 Refusal to approve an NDA.
- 21 CFR 314.150 Withdrawal of approval of an application or abbreviated application.
- 21 CFR 314.200 Notice of opportunity for hearing; notice of participation and request for hearing; grant or denial of hearing.
- 21 CFR 314.50 Content and format of an NDA.
- 21 CFR 314.90 Waivers.
- 21 CFR 330.10 Procedures for classifying OTC drugs as generally recognized as safe and effective and not misbranded, and for establishing monographs.